Trial site
St. Elisabeth Krankenhaus GmbH
Cologne, 50935, GermanyNot linked to an institution yet
- 14running trials
- 2closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 41 trial
- Status
- Recruiting7 trials
- Active, not recruiting6 trials
- Completed2 trials
- Not yet recruiting1 trial
- Lead sponsor
- Hoffmann-La Roche2 trials
- AGO Study Group1 trial
- AstraZeneca1 trial
- Charite University, Berlin, Germany1 trial
- Dominik Paul Modest1 trial
- and 10 more
Running trials
Not yet recruiting
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
NCT07004413· Phase 3· Charite University, Berlin, Germany· Source
Active, not recruiting
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
2025-523938-10-00· Phase 3· Eyepoint Inc.· Source
Recruiting
A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in patients with HR+/HER2- advanced breast cancer and disease progression despite prior hormone-based treatment (CAPIcorn)
2024-511392-15-00· Phase 3· WSG Women's Cancer Study Group GmbH· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
Pre-Operative Treatment in REseCTable COlon CanceR
NCT06899477· Phase 3· Dominik Paul Modest· Source
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
NCT06081244· Phase 3· Women's Cancer Study Group GmbH· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· Phase 3· Hoffmann-La Roche· Source
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· Phase 3· Gilead Sciences· Source
Recruiting
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
NCT05009082· Phase 3· AGO Study Group· Source
Recruiting
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
NCT05362760· Phase 4· Prof. Wolfgang Janni· Source
Active, not recruiting
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
NCT04111978· Phase 3· Swiss GO Trial Group· Source
Active, not recruiting
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
NCT04767594· Pfizer· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error